Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.
Also called NCT04206228
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 149 participants
- Sponsor
- Registry
-
NCT04206228
-
- Other papers using this trial's data
- Intravenous iron supplement for iron deficiency in patients with severe aortic stenosis scheduled for transcatheter aortic valve implantation: results of the IIISAS randomised trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Norway
- Registry status
- Completed
Technical summary
Registry record NCT04206228. Randomized; triple masking; primary purpose treatment. Start 2020-01-13 (actual); primary completion 2022-02-15 (actual). Results posted on 2026-04-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis
- Acronym
- IIISAS
- Condition
- Severe Aortic Stenosis
- Condition
- Iron-deficiency
- Intervention (Drug)
- Intravenous iron isomaltoside
- Intervention (Drug)
- Placebo
- Lead sponsor
- Oslo University Hospital
Record details
- Record id
cardio:ct-nct04206228- Content hash
09cd80e6f1b42ef0929f2ca9735a9457786daba286a41576278d0dd610643e51